Welcome to our dedicated page for Liquidia SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liquidia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liquidia's regulatory disclosures and financial reporting.
Liquidia Corp (LQDA) director Ramandeep Singh filed a Rule 144 notice covering the potential sale of common stock. The notice lists 9,024 shares of common stock held at Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $619,209.73, and indicates the shares are tied to a stock option exercise for cash, with a proposed sale date of September 11, 2026 on NASDAQ.
Liquidia Corp (LQDA) reported that Chief Human Resource Officer Sarah Krepp sold 274 shares of common stock on September 1, 2026 at a volume weighted average price of $67.76 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan and was made to cover taxes on settling Restricted Stock Units. After the sale, she directly held 117,308 shares, including multiple grants of unvested RSUs and shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corporation (LQDA) reports that the U.S. Food and Drug Administration has granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a serious, high-mortality autoimmune disease with no FDA-approved therapy specifically for SSc-RP.
Liquidia plans to start the RE-WARM Phase 2a study in October 2026 in about 75 adults with SSc experiencing symptomatic Raynaud's attacks, across up to 30 U.S. sites, with primary completion targeted for February 2027. YUTREPIA is already approved for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease but not for SSc-RP.
Liquidia Corp (LQDA) insider Jason Adair, Chief Business Officer, exercised stock options for a total of 31,799 shares of common stock at exercise prices of $9.31 and $14.20 per share and on the same date sold 73,631 shares at a volume-weighted average price of $69.0908 per share. The sales, including those of option exercise shares, were effected pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2025. Adair continues to hold common stock and multiple tranches of unvested RSUs in Liquidia.
Liquidia Corporation (LQDA) received a notice that officer Jason Adair intends to sell common stock under Rule 144. The notice covers up to 73,631 shares of common stock, based on a holding of 73,631 shares with an aggregate market value of $5,231,482.55 as of August 21, 2026, when 89,508,891 shares were outstanding. The planned sales relate to shares acquired through the exercise of stock options for 31,799 shares and the vesting of restricted stock units for 41,832 shares, all originally issued by Liquidia. A prior sale of 7,863 shares for $562,288.70 during the past three months is also disclosed.
Liquidia Corp (LQDA) director Katherine Rielly-Gauvin reported a two-day option exercise and share sale sequence under a Rule 10b5-1 trading plan. On August 19–20, 2026, she exercised non-qualified stock options for a total of 55,182 shares of common stock at exercise prices of $2.51 and $2.59 per share, and sold 55,182 shares of common stock in open-market transactions. The reported sales were at volume-weighted average prices of $74.9941 (range $73.28–$76.37) and $72.2273 (range $71.00–$74.35). Her reported holdings include 5,882 restricted stock units granted on June 16, 2026, none of which had vested as of this filing.
Liquidia Corp (LQDA) reported that its Chief Medical Officer, Rajeev Saggar, exercised a non-qualified stock option for 50,000 shares of common stock at an exercise price of $3.73 per share. On the same date, he sold 50,000 shares of common stock at a volume weighted average price of $74.06, and two days earlier sold an additional 29,534 shares at a volume weighted average price of $76.84. Following the option exercise, he continued to hold 150,000 stock options; separate footnote disclosure indicates additional holdings of unvested RSUs and shares acquired under the employee stock purchase plan.
Liquidia Corp (LQDA) received a notice that director Katherine T. Rielly-Gauvin plans to sell up to 55,182 shares of Liquidia common stock. The shares are to be obtained through the exercise of stock options with cash payment and sold through Morgan Stanley Smith Barney LLC.
The filing lists an aggregate market value of approximately $4,101,678.06 for the shares to be sold and indicates 89,508,891 Liquidia common shares outstanding as of 08/19/2026. The remarks state that the securities were and will be received upon option exercises over the next three months, with acquisition and payment occurring on the exercise/sale dates.
Liquidia Corp (LQDA) received a notice under Rule 144 for a planned resale of common stock by officer Rajeev Saggar. The notice covers 50,000 shares of common stock, to be acquired through a stock option exercise for cash on 08/19/2026 and sellable through Morgan Stanley Smith Barney on NASDAQ. Over the prior three months, Saggar reported Rule 144 sales of 29,534 shares on 08/17/2026 and 9,926 shares on 07/13/2026.
Liquidia Corporation (LQDA) reports a planned sale of up to 29,534 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $2,269,380.75. Shares outstanding were 89,508,891; this is a baseline figure, not the amount being sold. The sale is expected around 08/17/2026 on NASDAQ. The shares relate to vested equity awards, including Performance Shares and Restricted Stock. In the past three months, an affiliate, Rajeev Saggar, sold 9,926 common shares for $709,782.87.